Arlcyn 150 Tablet
Marketer
Cyno Pharmaceuticals Ltd
Salt Composition
Erlotinib (150mg)
Overview Arlcyn 150 Tablet
Arlcyn 150mg tablets treat non-small cell lung and pancreatic cancers. Administer on an empty stomach, or one hour before or two hours after eating. Continue this medication as directed by your physician; treatment duration is individualized. Follow your doctor's instructions precisely; improper dosage can cause severe adverse reactions. Therapeutic effects may take weeks or months to appear; do not discontinue without medical guidance. Common side effects include nausea, vomiting, tiredness, skin rashes, and weight loss. Severe diarrhea requires increased fluid intake or medical attention. Photosensitivity may occur; use protective clothing and sunscreen outdoors. Report mouth sores, vision changes, or breathing problems immediately. Liver function monitoring may be recommended. Inform your healthcare provider of all other medications you are taking, as interactions are possible. This medication is contraindicated during pregnancy and breastfeeding; reliable contraception is crucial for both partners. Smoking cessation is advised as it may interfere with the drug's efficacy. Maintain a two-hour interval between Arlcyn 150mg and antacids or other medications.
Primary Ingredients of Arlcyn 150 Tablet
No information provided. Please provide the text you wish me to rephrase.
Uses of Arlcyn 150 Tablet
Cancers of the pancreas and non-small cell lung
Major Benefits of Arlcyn 150 Tablet:
Consume this medication precisely as prescribed by your physician, adhering to both the dosage and treatment schedule. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Administer Arlcyn 150 Tablet on an empty stomach.
Common Side effects of Arlcyn 150 Tablet:
- Abdominal pain
- Bone pain
- Breathlessness
- Constipation
- Cough
- Diarrhea
- Fatigue
- Fever
- Infection
- Muscle pain
- Nausea
- Rash
- Stomatitis (Inflammation of the mouth)
- Vomiting
- Weight loss
How to use Arlcyn 150 Tablet:
Consume this medication precisely as directed by your physician, adhering to the prescribed dosage and timeframe. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Arlcyn 150 Tablets should be taken on an empty stomach.
How Arlcyn 150 Tablet works:
Arlcyn 150 Tablet combats lung cancer. Its mechanism involves targeting epidermal growth factor receptors (EGFR), surface proteins on lung cancer cells that regulate their proliferation. By attaching to EGFR and blocking its signaling, Arlcyn 150 Tablet disrupts the cancer's growth signals, thereby limiting tumor expansion.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside Arlcyn 150 Tablet lacks established safety data. Seek medical advice before combining them.
PregnancyCONSULT YOUR DOCTOR
Use of Arlcyn 150 Tablet is contraindicated during pregnancy due to established risk to the fetus. A physician might exceptionally prescribe it in life-threatening circumstances where potential benefits outweigh known hazards. Physician consultation is advised.
Breast feedingCONSULT YOUR DOCTOR
Lactation and Arlcyn 150 Tablet use are likely incompatible. Available human data indicate potential transfer of the drug into breast milk, posing a possible risk to the infant.
DrivingCONSULT YOUR DOCTOR
Arlcyn 150 Tablet's effect on driving ability is undetermined. Refrain from driving if you experience symptoms impairing concentration or reaction time.
KidneySAFE IF PRESCRIBED
Arlcyn 150 Tablet is suitable for patients with kidney disease, requiring no dosage alteration. However, its use is contraindicated in individuals with severe kidney impairment.
LiverCAUTION
Patients with liver impairment should exercise caution when using Arlcyn 150 Tablets. Dosage modification for Arlcyn 150 Tablets may be necessary. Physician consultation is advised.
What if you forget to take Arlcyn 150 Tablet :
Omit any missed Arlcyn 150 Tablet dose; resume your regular dosing regimen. Avoid taking a double dose.
Facts to Know About Arlcyn 150 Tablet
| Label | Value |
|---|---|
| Chemical Category | Quinazoline-based compound |
| Developing Habits | No. |
| Treatment Category | Cancer Medications |


